Biotechnological companies using AI
Genmab A/S (Nasdaq: GMAB) announced a partnership with Anthropic on January 8, 2026, to enhance its research and development (R&D) processes through the adoption of agentic artificial intelligence (AI) capabilities. This collaboration aims to design and deploy custom, Claude--powered AI solutions to support Genmab's clinical development priorities, accelerating data processing, analysis, and document generation.